Oriva Therapeutics is a clinical-stage women’s health biotechnology company focused on the development of first-in-class and best-in-class therapies for chronic, prevalent gynecological diseases with high unmet medical need. Based in Barcelona, the company has been created to advance innovative and disease-modifying approaches that aim to improve both clinical outcomes and quality of life for women. Oriva Therapeutics’ pipeline is built around two advanced programs in endometriosis and uterine fibroids, leveraging novel chemistry targeting validated biological pathways and differentiated from existing treatment options.